Description of Operations and Summary of Significant Accounting Policies (Details) (USD $)	0 Months Ended		9 Months Ended			9 Months Ended	12 Months Ended		9 Months Ended
	Jun. 02, 2014	Jun. 01, 2014	Sep. 30, 2014	Dec. 31, 2013		Sep. 30, 2014 VIBATIV	Dec. 31, 2013 VIBATIV	Sep. 30, 2014 Theravance Biopharma Common stock	Sep. 30, 2014 GSK LABA collaboration and Strategic Alliance agreements
Description of operations and summary of significant accounting policies
Percentage of economic interest in any future payments made under the agreements									15.00%
Business Separation
Cash, cash equivalents and marketable securities contributed to Theravance Biopharma		$ 393,000,000
Number of ordinary shares of Theravance Biopharma issued for every share of Theravance	0.286
Number of ordinary shares owned as marketable securities (in shares)								436,802
Inventories
Raw materials				5,138,000
Work-in-process				360,000
Finished goods				4,908,000
Total inventories			0	10,406,000	[1]
Allowance for doubtful accounts
Allowance for doubtful accounts							0
Product Revenues
Revenue from product sales						$ 0	$ 0
Cash discounts (as a percent)						2.00%
Expired product return acceptance period prior to product expiration date						6 months
Expired product return acceptance period after product expiration date						12 months
Intangible Assets
Estimated useful life			15 years

[1] Condensed consolidated balance sheet at December 31, 2013 has been derived from audited consolidated financial statements.